Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling

Andy J Minn; E John Wherry

doi:10.1016/j.cell.2016.03.031

Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling

Cell. 2016 Apr 7;165(2):272-5. doi: 10.1016/j.cell.2016.03.031.

Authors

Andy J Minn¹, E John Wherry²

Affiliations

¹ Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: andyminn@mail.med.upenn.edu.
² Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

PMID: 27058661
DOI: 10.1016/j.cell.2016.03.031

Abstract

Improving efficacy of immune checkpoint blockade for cancer can be facilitated by combining these agents with each other and/or with other conventional or targeted therapies. Interferon and innate immune signaling pathways in immune and tumor cells have emerged as intriguing determinants of response and resistance, often in complex and seemingly paradoxical ways.

Publication types

Review

MeSH terms

Animals
Humans
Immune Tolerance
Immunity, Innate
Interferons / metabolism*
Lymphocytes / immunology
Neoplasms / immunology*
Neoplasms / metabolism
Neoplasms / therapy*
Signal Transduction*

Substances

Interferons